Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Summary

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Eligibility

Inclusion Criteria:

* Has cognitive ability to provide informed consent
* Aged 22 years or older
* Hospitalized with hypoxemia/respiratory distress
* Diagnosis of COPD
* Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
* Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)

Exclusion Criteria:

* Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
* Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
* Patient receiving end of life care
* Nasal or facial conditions precluding use of nasal high flow
* Pregnancy or breastfeeding
* Cognitive impairment or impaired consciousness precluding informed consent
* Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
* Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
* The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
* Has already participated in this clinical trial

Conditions1

Locations3 sites

Find trials near these locations

Browse More Trials